Holen Sie sich die Stockscreener-App
25.16
3.49%
-0.91
Handel nachbörslich:
25.16
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$26.07
Offen:
$26
24-Stunden-Volumen:
1.61M
Relative Volume:
0.82
Marktkapitalisierung:
$2.24B
Einnahmen:
$333.87M
Nettoeinkommen (Verlust:
$-169.00M
KGV:
-12.33
EPS:
-2.04
Netto-Cashflow:
$-157.30M
1W Leistung:
+2.11%
1M Leistung:
-7.87%
6M Leistung:
+86.51%
1J Leistung:
+47.05%
1-Tages-Spanne:
$25.13
$26.02
1-Wochen-Bereich:
$24.57
$27.20
52-Wochen-Spanne:
$12.91
$28.69
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
25.16 | 2.32B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Joplin Globe
Will Travere Therapeutics Inc. price bounce be sustainableQuarterly Investment Review & Fast Moving Trade Plans - newser.com
What moving averages say about Travere Therapeutics Inc.Quarterly Investment Review & Stepwise Entry/Exit Trade Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Travere rises as FDA says no AdCom required for Filspari label expansion - MSN
Focal Segmental Glomerulosclerosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Retrophin, AbbVie, AstraZeneca, Pfizer, Sanofi, Teva Pharma - The Globe and Mail
How to recover losses in Travere Therapeutics Inc. stock2025 Technical Patterns & Safe Capital Growth Trade Ideas - newser.com
Can Travere Therapeutics Sustain Its 48.9% Rally Amid Pipeline Progress in 2025? - Yahoo Finance
Can trapped investors hope for a rebound in Travere Therapeutics Inc.Market Performance Report & Technical Pattern Recognition Alerts - newser.com
What dividend safety score for Travere Therapeutics Inc. stockQuarterly Trade Summary & Free Verified High Yield Trade Plans - newser.com
What candlestick patterns are forming on Travere Therapeutics Inc.Market Activity Summary & Breakout Confirmation Alerts - newser.com
Will Travere Therapeutics Inc. stock deliver consistent dividendsMarket Activity Recap & Weekly Momentum Picks - newser.com
Real time breakdown of Travere Therapeutics Inc. stock performanceJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Travere therapeutics CFO sells $104,463 in stock - MSN
Building trade automation scripts for Travere Therapeutics Inc.Bond Market & Real-Time Market Sentiment Alerts - newser.com
Heatmap analysis for Travere Therapeutics Inc. and competitors2025 Volatility Report & Fast Entry and Exit Trade Plans - newser.com
Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday? - MSN
Published on: 2025-10-03 01:41:47 - newser.com
Why Travere Therapeutics Inc. stock remains on watchlists2025 Buyback Activity & Verified Short-Term Trading Plans - newser.com
Using data tools to time your Travere Therapeutics Inc. exit2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Travere Therapeutics stock rises on sNDA submission plans for FILSPARI - MSN
How to use a screener to detect Travere Therapeutics Inc. breakoutsGap Up & Risk Controlled Stock Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Trading Down 7.6%What's Next? - MarketBeat
Travere therapeutics CAO Calvin Sandra sells $17,520 in stock - MSN
Published on: 2025-09-29 13:53:58 - newser.com
Published on: 2025-09-29 12:50:11 - newser.com
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Travere therapeutics CEO Eric M. Dube sells $273,455 in stock - MSN
Is GAIL India Limited One of the Top Picks for Growth Investors in YEARFlag and Pennant Patterns & Free Phenomenal Trading Returns - earlytimes.in
Published on: 2025-09-28 13:45:23 - earlytimes.in
Published on: 2025-09-28 02:30:57 - newser.com
Travere Therapeutics Inc Stock Analysis and ForecastMarket Profile Overview & Double Digit Returns - earlytimes.in
How FILSPARI’s Endorsement as First-Line Therapy Has Changed Travere Therapeutics’ (TVTX) Investment Story - Sahm
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy - Business Wire
Travere Therapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| REED ELIZABETH E | Chief Legal Officer and GC |
Sep 22 '25 |
Sale |
25.00 |
10,000 |
250,000 |
89,878 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):